Abstracts tagged "risk assessment"

Abstract Number: 0558 • ACR Convergence 2020
Statin Use Pattern in Patients with Inflammatory Joint Disease in a Single Site VA Medical Center
Lenche Kostadinova¹, Sofi Damjanovska², Angela Gupta³, Ibtissam Gad⁴, Sameena Syed⁴, Alyssa Lange⁵, Corinne Kowal⁶, Carey Shive⁷, Christopher Burant⁴, Brigid Wilson⁴, David Canaday⁴, David Zidar⁸, Donald Anthony⁹ and Maya Mattar¹⁰, ¹(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Highland Heights, OH, ²(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, OH, ³(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, ⁴(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, ohio, ⁵Case Western Reserve University, Cleveland, ⁶Case western reserve university/Cleveland VA Medical Center, ohio, ⁷(2) Department of Pathology, Case Western Reserve University, ohio, ⁸Case Western Reserve University/Cleveland VA Medical Center, Cleveland, ⁹Case Western Reserve University/Cleveland VA Medical Center/MetroHealth Medical Center, Cleveland, OH, ¹⁰Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, OH
Background/Purpose: Patients with inflammatory joint disease, including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) carry increased risk of cardiovascular disease (CVD). Mechanisms…
Abstract Number: 1751 • ACR Convergence 2020
Forecasting Healthcare Utilization in Rheumatoid Arthritis: A Machine Learning Predictive Model of Emergency Department Visits and Prednisone Initiation in a Single Tertiary Academic Center
Elston He¹, Eli Cornblath², Pratyusha Yalamanchi³, Alexis Ogdie², Joshua Baker² and Michael George², ¹Synovium, Inc., Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Michigan Medicine, Ann Arbor, MI
Background/Purpose: Despite recent advances in therapy, 42% of patients with rheumatoid arthritis (RA) nationwide had moderate or high disease activity at their most recent visit.…
Abstract Number: 0730 • ACR Convergence 2020
To Taper or Not to Taper in Juvenile Idiopathic Arthritis: Is There a Risk of Development of Uveitis Flares?
Maria Teran¹, Alina Lucica Boteanu², Carlos Guillen¹, Cristina Pijoan¹, Jose Quinones¹, Veronica Garcia³, Ivan Del Bosque-Granero³, Laura Calvo-Sanz⁴ and Mónica Vázquez⁴, ¹Hospital Ramon y Cajal, Madrid, Madrid, Spain, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy, ³Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ⁴Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain
Background/Purpose: To determine the association between the occurrence of uveitis flares in patients with Juvenile Idiopathic Arthritis (JIA) and the de-intensification of immunosuppressive treatment.Methods: We…
Abstract Number: 0759 • ACR Convergence 2020
Presence of Ultrasound Imaging Biomarkers Are Good Predictors of Arthritis Development in a Population at Risk for Rheumatoid Arthritis
Yogan Kisten¹, Alexandra Circiumaru¹, Malena Loberg-Haarhaus², Nancy Vivar², Aleksandra Antovic³, Hamed Rezaei², Erik Af Klint¹, Aase Hensvold¹ and Anca Catrina¹, ¹Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ²Rheumatology clinic, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ³Center for Rheumatology, Academic Specialist Center, Stockholm Health Region, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden
Background/Purpose: Ultrasound (US) imaging biomarkers in the context of Anti-Citrullinated Protein Antibody (ACPA) autoimmunity might play an important role in the very early detection of…
Abstract Number: 045 • 2020 Pediatric Rheumatology Symposium
No-Shows: a Search for Modifiable Risk Factors
Samantha Ong ¹, Xujia Li ¹ and Austin Dalrymple², ¹Saint Louis University School of Medicine, St. Louis, ²Saint Louis University School of Medicine, Saint Louis, Missouri
Background/Purpose: Missed ambulatory visits, or “no-shows,” limit patient access, increase costs, occupy provider time, and lead to worse patient outcomes. Only a few studies have…
Abstract Number: 1758 • 2019 ACR/ARP Annual Meeting
Development of Ultrasound Detectable Arthritis Among ACPA Positive Subjects with Musculoskeletal Symptoms: The Risk RA Prospective Study
Aase Hensvold¹, Yogan Kisten ², Alexandra Circiumaru ¹, Monika Hansson ³, Meng Sun ¹, Guozhong Fei ⁴, Nancy Vivar ², Erik af Klint ², Hamed Rezaei ², Lars Klareskog ³, Aleksandra Antovic ⁵ and Anca Catrina ³, ¹Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, ²Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ³Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁴Center for Rheumatology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden, Stockholm, Sweden, ⁵Center for Rheumatology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden
Background/Purpose: Studies have shown that anti-citrullinated protein antibodies (ACPA) are a risk factor for the development of arthritis. We aimed to investigate in a prospective…
Abstract Number: 1960 • 2019 ACR/ARP Annual Meeting
Pleiotropy of Genetic Predisposition to Rheumatoid Arthritis Increases the Risk for Autoimmune Disease
Vivian Kawai¹, Mingjian Shi ¹, Qiping Feng ², Cecilia Chung ¹, Ge Liu ², Nancy Cox ², Dan Roden ², C. Michael Stein ¹ and Jonathan Mosley ², ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disorder that is associated with increased risk of cardiovascular disease, cardiometabolic disorders, and autoimmune disease. Thus, we…
Abstract Number: 2136 • 2019 ACR/ARP Annual Meeting
Cardiovascular Risk Evaluation in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Preliminary Results from the “Cardiovascular Obesity and Rheumatic DISease (CORDIS)” Study Group of the Italian Society of Rheumatology
Fabio Cacciapaglia¹, Gian Luca Erre ², Garifallia Sakellariou ³, Ombretta Viapiana ⁴, Matteo Piga ⁵, Elena Bartoloni ⁶, Andreina Manfredi ⁷, Sergio Colella ¹, Floriana Castagna ², Giacomo Cafaro ⁸, Martina Dessì ⁵, Marco Fornaro ¹, Alessandro Giollo ⁹, Silvia Grignaschi ¹⁰, Caterina Vacchi ¹¹, Francesca Romana Spinelli ¹², Fabiola Atzeni ¹³ and Elisa Gremese ¹⁴, ¹Rheumatology Unit – Department of Emergency and Organs Transplantation, University and AOU Policlinico of Bari, Italy, Bari, Italy, ²Specialità Mediche, Azienda Ospedaliero Universitaria di Sassari, Italy., Sassari, Italy, ³Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ⁴University of Verona, Verona, Italy, ⁵Rheumatology Unit, Department of Medical Sciences, University and AOU Policlinico of Cagliari, Italy., Cagliari, Italy, ⁶Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy, Perugia, Italy, ⁷Rheumatology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Emilia-Romagna, Italy, ⁸Rheumatology Unit, Department of Medicine, University of Perugia, Italy., Perugia, Italy, ⁹Rheumatology Unit, Department of Medicine, University of Verona, Italy., Verona, Italy, ¹⁰Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy., Pavia, Italy, ¹¹Rheumatology Unit, Department of Medical and Surgical Science, University and AOU Policlinico of Modena, Italy., Modena, ¹²Rheumatology, Department of Internal Medicine and Medical Speciality, Sapienza University of Rome, Italy., Rome, Italy, ¹³Rheumatology Unit, University of Messina, Messina, Italy., Messina, Italy, ¹⁴Fondazione Policlinico Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients present high cardiovascular (CV) morbidity and mortality. International guidelines suggest estimating CV-risk in these patients,…
Abstract Number: 2322 • 2019 ACR/ARP Annual Meeting
Toward Cardiovascular Risk Stratification in Rheumatoid Arthritis: Use of Regression Tree Analyses to Evaluate Impact of Serum Biomarkers and Cardiovascular Risk Factors on Carotid Intima Media Thickness
Kimberly Liang¹, Yaming Li ¹, Suresh Mulukutla ¹, Steven Reis ¹, Marc Levesque ¹, Donald Jones ¹, Rachel Gartland ¹, Jennifer Avolio ¹, Ali Hakim Shoushtari ¹, Flordeliza Villanueva ¹, Larry Moreland ¹ and Douglas Landsittel ², ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, RI
Background/Purpose: Both traditional cardiovascular (CV) risk factors and disease-related factors contribute to the increased risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA). Mechanisms of…
Abstract Number: 2539 • 2019 ACR/ARP Annual Meeting
Patient Perception of Benefit and Risks Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus (SLE)
Sooyeon Kwon¹, Jessica Farrell ², Sarfaraz Hasni ³ and Shubhasree Banerjee ², ¹The Center For Rheumatology, Loudonville, NY, ²The Center for Rheumatology, LLC, Albany, NY, ³NIAMS, National Institutes of Health, Bethesda, MD
Background/Purpose: Hydroxychloroquine (HCQ) is recommended in all patients with systemic lupus erythematosus (SLE). Studies suggest that a significant proportion of subjects are non-adherent to daily…
Abstract Number: 889 • 2016 ACR/ARHP Annual Meeting
The Utility of Patient-Reported Outcomes in Predicting Disease Activity in Patients with Takayasu’s Arteritis
Antoine G. Sreih¹, Tanaz A. Kermani², Gunnar Tomasson³, Joshua F. Baker⁴, David Cuthbertson⁵, Renee Borchin⁶, Simon Carette⁷, Lindsy J. Forbess⁸, Gary S. Hoffman⁹, Nader A. Khalidi¹⁰, Curry L. Koening¹¹, Carol A. McAlear¹², Paul A. Monach¹³, Larry W. Moreland¹⁴, Christian Pagnoux¹⁵, Philip Seo¹⁶, Robert F. Spiera¹⁷, Kenneth J. Warrington¹⁸, Steven R. Ytterberg², Carol A. Langford¹⁹ and Peter A. Merkel²⁰, ¹Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Dept of Public Health Sciences, University of Iceland, Reykjavik, IS, ⁴Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁶University of South Florida, Tampa, FL, ⁷Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁸Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Rheumatology, Cleveland Clinic, Cleveland, OH, ¹⁰Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ¹¹Rheumatology, University of Utah, Salt Lake City, UT, ¹²University of Pennsylvania, Philadelphia, PA, ¹³Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁴Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁵Division of Rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Canada, Toronto, ON, Canada, ¹⁶Medicine, Johns Hopkins University, Baltimore, MD, ¹⁷Hospital for Special Surgery, Cornell, New York, NY, ¹⁸Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN, ¹⁹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²⁰Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA
Background/Purpose: Takayasu’s arteritis (TAK) is a relapsing large vessel vasculitis. There are currently no reliable predictors of disease relapse. This study explored whether changes in…
Abstract Number: 2018 • 2016 ACR/ARHP Annual Meeting
A Clinical Risk Prediction Model for Skin Thickness Progression in Early Diffuse Scleroderma
Robyn T. Domsic¹, Mary Lucas², Virginia D. Steen³ and Thomas A. Medsger Jr.⁴, ¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh Scleroderma Center, Pittsburgh, PA, ³Rheumatology, Georgetown University Medical Center, Washington, DC, ⁴Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Systemic sclerosis (SSc) is a rapidly evolving field with multiple potential therapeutic agents under development and several active clinical trials focused on treating…
Abstract Number: 2430 • 2015 ACR/ARHP Annual Meeting
Immunological Risk Factors after Rituximab Therapy in Patients with Pediatric Rheumatic Diseases – a Prospective Single-Center Study
Fabian Speth¹, Johannes Peter Haas¹ and Claas Hinze², ¹German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ²Department of Pediatric Rheumatology and Immunology, University Hospital Münster, Münster, Germany
Background/Purpose: Rituximab (RTX) is used in refractory pediatric rheumatic diseases (PRD). Data regarding the effects of RTX on the immune system in children and safety…
Abstract Number: 2940 • 2015 ACR/ARHP Annual Meeting
Risk Factors for Late-Onset Thrombosis in Systemic Lupus Erythematosus (SLE)
Khawla Al-Ghanim¹, Jiandong Su², Stacey E. Morrison³, Samar Alharbi⁴, Mohammed Attar⁵, Dafna Gladman², Murray Urowitz^6,7 and Jorge Sánchez-Guerrero⁸, ¹Rheumatology, TWH, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Div Rheumatology Rm MP-10-304, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, University Health Network, Toronto, ON, Canada, ⁵Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: Thrombotic events (TE) cause great morbidity and mortality in SLE patients. Studies of TE in SLE focus on early-onset TE. While the incidence of…
Abstract Number: 166 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Gout Attack Recurrence during Urate-Lowering Allopurinol Treatment
Myeong Jae Yoon¹, Ji Ae Yang², Sang Hyun Joo¹, Sang Jin Lee¹, Jin Young Moon¹, Hyun Mi Kwon¹, Dong Jin Ko¹, Yeong Wook Song¹ and Eun Bong Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Background/Purpose Gout is a recurrent inflammatory arthritis caused by crystal deposition of monosodium urate, which can be prevented urate-lowering agents such as allopurinol. However, gout…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].